Division of Nephrology, Dialysis, and Kidney Transplant, Foundation IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy.
Division of Gastroenterology and Hepatology, Foundation IRCCS Cà Granda Ospedale Maggiore Policlinico, Italy.
Nefrologia (Engl Ed). 2024 Jul-Aug;44(4):486-495. doi: 10.1016/j.nefroe.2024.01.021.
Hepatitis C virus infection and chronic kidney disease are major public health issues all over the world. It has been suggested a role of HCV as a risk factor for the development and progression of chronic kidney disease (defined by reduced glomerular filtration rate and/or detectable proteinuria) in the general population but conflicting findings have been given.
A systematic review of the published medical literature was conducted to assess whether positive HCV serologic status is associated with greater rate of proteinuria in the adult general population. We used a random-effect model to generate a summary estimate of the relative risk of proteinuria with HCV across the published studies.
We identified 23 studies (n=198,967 unique patients) and performed separate meta-analyses according to the study design. Overall effect estimate was significant in cross-sectional (OR, 1.47, 95%CI, 1.3; 1.66) (P<0.001) and obvious between-study heterogeneity was observed (Q value by Chi-squared [χ] test 27.3, P=0.02). The risk of proteinuria after exposure to HCV was also consistent among longitudinal studies (HR, 1.79, 95% CI, 1.17; 2.74) (P<0.001) and between-study heterogeneity occurred (Q value, 27.82 by X test, P=0.0001). Stratified analysis did not report heterogeneity in several comparisons-pooling studies based on urine protein/creatinine ratio (UACR) showed that the adjusted OR with HCV was 1.64 (95% CI, 1.41; 1.91, P<0.001) without heterogeneity (Q value by Chi-squared [χ] test 9.98, P=NS). Meta-regression recorded a link between greater prevalence of proteinuria in males with HCV exposure (P=0.03). Studies based on univariate analysis (n=6, n=72, 551 unique patients) gave similar results, pooled OR 1.54 (95% CI, 1.08; 2.19) (P=0.0001).
An important relationship between HCV infection and higher risk of proteinuria in the general population exists. Research aimed to understand the biological mechanisms underlying such association is under way. We encourage to screen all patients with HCV exposure for proteinuria.
丙型肝炎病毒(HCV)感染和慢性肾脏病是全球主要的公共卫生问题。有研究表明,HCV 是普通人群中慢性肾脏病(肾小球滤过率降低和/或可检测蛋白尿)发展和进展的一个危险因素,但也有相互矛盾的发现。
对已发表的医学文献进行系统回顾,以评估 HCV 阳性血清状态是否与成人普通人群中蛋白尿发生率的增加有关。我们使用随机效应模型生成了发表研究中 HCV 相关蛋白尿的相对风险的综合估计值。
我们共确定了 23 项研究(n=198967 例独特患者),并根据研究设计进行了单独的荟萃分析。横断面研究的总体效应估计值有统计学意义(OR,1.47,95%CI,1.30-1.66)(P<0.001),且观察到明显的研究间异质性(Q 值由卡方检验[χ]27.3,P=0.02)。在纵向研究中,暴露于 HCV 后发生蛋白尿的风险也一致(HR,1.79,95%CI,1.17-2.74)(P<0.001),且存在研究间异质性(Q 值,X2 检验 27.82,P=0.0001)。分层分析显示,基于尿蛋白/肌酐比值(UACR)的汇总研究无异质性,调整后的 OR 为 1.64(95%CI,1.41-1.91,P<0.001)(Q 值由卡方检验[χ]27.82,P=NS)。Meta 回归记录了 HCV 暴露男性蛋白尿发生率较高之间的关联(P=0.03)。基于单变量分析(n=6,n=72,551 例独特患者)的研究得出了类似的结果,汇总 OR 为 1.54(95%CI,1.08-2.19)(P=0.0001)。
HCV 感染与普通人群中蛋白尿风险增加之间存在重要关系。正在进行旨在了解这种关联背后的生物学机制的研究。我们鼓励对所有 HCV 暴露患者进行蛋白尿筛查。